Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Genitourinary System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm

Cancer Family

Genitourinary System Neoplasm

CI-CAN-00000018Explore in graph →

Non-malignant3,849 active trials61 approved drugs306 evidence items

NCIt: C156482

Overview
Statistics
Survival
Genomics114
Variants & evidence306
Drugs75
Trials17388
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (892)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 701–725 of 892 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
· J Clin Oncol · 2009 · PMID 19667267 · validated civic_curation pubmed
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
· J Clin Oncol · 2013 · PMID 23569316 · validated civic_curation pubmed
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
· Clin Cancer Res · 2014 · PMID 24240112 · validated civic_curation pubmed
Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.
· Br J Cancer · 2013 · PMID 23329234 · validated civic_curation pubmed
Toward the molecular dissection of peritoneal pseudomyxoma.
· Ann Oncol · 2016 · PMID 27502722 · validated civic_curation pubmed
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed
Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.
· Tumour Biol · 2015 · PMID 25544710 · validated civic_curation pubmed

Showing 701–725 of 892 publications

← Previous
1
…
28
29
30
…
36
Next →

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

· Gynecol Oncol · 2016 · PMID 26740259 · validated civic_curation pubmed

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

· Lancet Oncol · 2014 · PMID 25218906 · validated civic_curation pubmed

The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.

· PLoS One · 2015 · PMID 26422378 · validated civic_curation pubmed

Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.

· JAMA · 2010 · PMID 21177507 · validated civic_curation pubmed

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

· Lancet Oncol · 2011 · PMID 21862407 · validated civic_curation pubmed

CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis.

· Int J Clin Exp Med · 2015 · PMID 26629066 · validated civic_curation pubmed

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

· Lancet Oncol · 2017 · PMID 27908594 · validated civic_curation pubmed

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

· J Clin Oncol · 2017 · PMID 27870574 · validated civic_curation pubmed

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

· J Clin Oncol · 2015 · PMID 26324363 · validated civic_curation pubmed

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.

· J Transl Med · 2016 · PMID 27154293 · validated civic_curation pubmed

Decreased ARID1A expression correlates with poor prognosis of clear cell renal cell carcinoma.

· Hum Pathol · 2015 · PMID 25628030 · validated civic_curation pubmed

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

· Br J Cancer · 2012 · PMID 23099803 · validated civic_curation pubmed

Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

· N Engl J Med · 2012 · PMID 22187960 · validated civic_curation pubmed

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.

· EBioMedicine · 2018 · PMID 29941343 · validated civic_curation pubmed

MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.

· J Clin Oncol · 2020 · PMID 32822286 · validated civic_curation pubmed

Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor.

· Iran J Kidney Dis · 2011 · PMID 21525573 · validated civic_curation pubmed

ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

· Gynecol Oncol · 2019 · PMID 30797591 · validated civic_curation pubmed

ETV6-NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study.

· Pediatr Blood Cancer · 2018 · PMID 29286563 · validated civic_curation pubmed